Project Completes with Release of Drug Discovery Platform

The partnership behind the Innovate UK funded DeepADMET project, has successfully developed a software platform that will support the design of new drug candidates. In collaboration with global pharma and biotech companies, the consortium- software developer Optibrium, AI company  Intelligens and the UK’s Medicines Discovery Catapult (MDC) - demonstrated the ability of its new AI platform, Cerella™, to identify compounds with improved ‘on target’ properties more efficiently and was proven to reduce costs and shorten discovery cycle times.

Matthew Segall, CEO at Optibrium said: “We appreciate the support received from Innovate UK, enabling us to advance the development of our AI platform, Cerella. As proven by several case studies, Cerella fills a critical need in modern drug discovery, with collaborators’ research and development teams eager to exploit its capacity to accelerate their discovery of novel breakthrough treatments. We are grateful for Innovate UK’s initiatives that enable collaborations like ours, and will continue to work with Intellegens and MDC to further the UK’s role in drug discovery.”

Ben Pellegrini, CEO at Intellegens: “This project represents a significant step forward for Intellegens. Through this collaborative project, we have validated the underlying science with some of the biggest pharma companies in the world, and more importantly, wrapped it up in a robust, deployable platform. We look forward to building on this technology and continuing our collaboration with Optibrium.”

John P. Overington, Chief Informatics Officer at Medicines Discovery Catapult: “The power that comes from discovering and preparing the data needed for medicines research cannot be overstated. This project is unequivocal in its demonstration of how quality data can refine, direct and expedite drug discovery, resulting in faster and flexible routes to the clinic while minimising overall project costs.”

“It has been an extremely rewarding venture working with Optibrium and Intellegens during this project; a collaboration which will enable a more streamlined and efficient approach to drug discovery and be able to see future applications in other key business areas.”